No Data
Major Shareholder Boosts Investment in Orchestra BioMed Holdings!
Orchestra BioMed Receives US FDA Approval for Heart Device Trial
Orchestra BioMed Holdings: FDA Approves IDE Amendment To Initiate Updated Design Of Virtue SAB In Treatment Of Coronary ISR Trial
Express News | Orchestra Biomed Holdings Inc: Targeting Initiation of Virtue Trial During Second Half of 2025
Express News | Orchestra Biomed Receives FDA Approval of Ide to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-Angioinfusion Balloon, Virtue SAB, Head-to-Head With Paclitaxel-Coated Balloon
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head With Paclitaxel-Coated Balloon
